LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

Search

Maravai LifeSciences Holdings Inc (Class A)

Fermé

SecteurSoins de santé

5.07 -0.39

Résumé

Variation du prix de l'action

24h

Actuel

Min

5.01

Max

5.29

Chiffres clés

By Trading Economics

Revenu

36M

-3.7M

Ventes

16M

66M

BPA

0.01

Marge bénéficiaire

-5.67

Employés

416

EBITDA

57M

15M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+11.18% upside

Dividendes

By Dow Jones

Prochains Résultats

10 août 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

454M

1.9B

Ouverture précédente

5.46

Clôture précédente

5.07

Sentiment de l'Actualité

By Acuity

50%

50%

153 / 344 Classement par Healthcare

Maravai LifeSciences Holdings Inc (Class A) Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

10 juin 2026, 23:36 UTC

Résultats

Correction to Oracle Reports Higher 4Q Profit Article

10 juin 2026, 23:19 UTC

Actions en Tendance

Stocks to Watch: Oracle, Oxford Industries, Humacyte, PureCycle Technologies

10 juin 2026, 23:09 UTC

Principaux Mouvements du Marché

PureCycle Technologies Slides on Offerings of Stock and Convertible Notes

10 juin 2026, 23:04 UTC

Résultats

Oracle Reports Higher 4Q Profit on Surging Cloud Revenue -- Update

10 juin 2026, 20:44 UTC

Principaux Mouvements du Marché

Caterpillar Raises Quarterly Dividend 8%

10 juin 2026, 23:49 UTC

Acquisitions, Fusions, Rachats

Elliott: Northern Star Should Take No Options Off The Table

10 juin 2026, 23:48 UTC

Acquisitions, Fusions, Rachats

Elliott: Reiterates Call For Formal Strategic Review of Northern Star

10 juin 2026, 23:48 UTC

Acquisitions, Fusions, Rachats

Elliott: Northern Star Board Must Be Substantially Strengthened Beyond 1 Additional Director

10 juin 2026, 23:47 UTC

Market Talk

Nintendo's Stock Recovery Likely Deferred Without Mario Game -- Market Talk

10 juin 2026, 23:47 UTC

Acquisitions, Fusions, Rachats

Elliott: Board Letter Indicates It Doesn't Understand Magnitude of Change Required

10 juin 2026, 23:46 UTC

Acquisitions, Fusions, Rachats

Elliott Investment Management: Northern Star Letter Validates Investment Thesis

10 juin 2026, 23:38 UTC

Market Talk

Global Equities Roundup: Market Talk

10 juin 2026, 23:38 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

10 juin 2026, 23:38 UTC

Market Talk

Nikkei Likely to Fall on Renewed Concerns About Iran Conflict -- Market Talk

10 juin 2026, 23:32 UTC

Market Talk

Oil Rises Amid Escalating Supply-Disruption Fears -- Market Talk

10 juin 2026, 23:20 UTC

Market Talk

Wesfarmers's Bunnings Business Looks Resilient to Macro Headwinds -- Market Talk

10 juin 2026, 22:05 UTC

Market Talk

Correction to Bank of Canada Stays on Hold Market Talk

10 juin 2026, 21:57 UTC

Résultats

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

10 juin 2026, 21:52 UTC

Résultats

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

10 juin 2026, 21:35 UTC

Résultats

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

10 juin 2026, 21:22 UTC

Résultats

Oracle Stock Slides on Increased Capital Spending -- WSJ

10 juin 2026, 20:50 UTC

Market Talk
Résultats

Tech, Media & Telecom Roundup: Market Talk

10 juin 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

10 juin 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

10 juin 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

10 juin 2026, 20:39 UTC

Market Talk
Résultats

Oracle Needs to Raise Less Capital to Fund Data-Center Buildout -- Market Talk

10 juin 2026, 20:34 UTC

Résultats

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

10 juin 2026, 20:33 UTC

Résultats

This 'Amazon for Travel' Firm Beat Earnings Expectations. The Stock Is Soaring. -- Barrons.com

10 juin 2026, 20:33 UTC

Market Talk
Résultats

Global Equities Roundup: Market Talk

10 juin 2026, 20:33 UTC

Market Talk
Résultats

Oracle Health Expected to Grow Double-Digits This Fiscal Year -- Market Talk

Comparaison

Variation de prix

Maravai LifeSciences Holdings Inc (Class A) prévision

Objectif de Prix

By TipRanks

11.18% hausse

Prévisions sur 12 Mois

Moyen 5.67 USD  11.18%

Haut 6 USD

Bas 5 USD

Basé sur 5 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

5 ratings

3

Achat

2

Maintien

0

Vente

Sentiment

By Acuity

153 / 344Classement par Soins de santé

Sentiment de l'Actualité

Neutral

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Moyen

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Maravai LifeSciences Holdings Inc (Class A)

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.
help-icon Live chat